CoChat

Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection

Open access

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The global polio eradication campaign has had remarkable success in reducing wild-type poliovirus infection, largely built upon the live attenuated Sabin oral poliovirus vaccine. Whilst rare, vaccine poliovirus strains may cause infection and subsequently revert to a neurovirulent type, termed vaccine-derived poliovirus (VDPV). Persistent, vaccine derived infection may occur in an immunocompromised host (iVDPV), where it is a recognised complication following receipt of the Sabin vaccine. This has significant implications for the global polio eradication campaign and there is currently no agreed global strategy to manage such patients.Here we describe a case of a 50-year-old man with common variable immune deficiency, persistently infected with a neurovirulent vaccine-derived type 2 poliovirus following vaccination in childhood. iVDPV infection had proven resistant to multiple prior attempts at treatment with human breast milk, ribavirin and oral administration of a normal human pooled immunoglobulin product. His iVDPV infection subsequently resolved after 12 days treatment with remdesivir, an adenosine analogue prodrug that is an inhibitor of viral RNA-dependent RNA polymerase, administered as treatment for a prolonged, moderate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. iVDPV from the patient, isolated prior to treatment, was subsequently demonstrated to be sensitive to remdesivir in vitro. Based on the observations made in this case, and the mechanistic rationale for use with iVDPV, there is strong justification for further clinical studies of remdesivir treatment as a potentially curative intervention in patients with iVDPV infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1135834

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patient iVDPV sequence evolution and molecular clock analysis. .
Figure 1 Patient iVDPV sequence evolution and molecular clock analysis. .CC BY · PubMed Central
Figure 2 (A) A graphical representation of clinical timeline and relevant microbiological results. (B) iVDPV stool viral load on serial samples tested at the National Institute for Biological Standards and Control (NIBSC). Unsuccessful trials of treatment for iVDPV are displayed from 1999 to 2003. Persistent iVDPV carriage is then demonstrated to last positive sample, November 2018. Initial negative stool samples following remdesivir therapy are shown. Patient stool samples remain negative to August 2022.
Figure 2 (A) A graphical representation of clinical timeline and relevant microbiological results. (B) iVDPV stool viral load on serial samples tested at the National Institute for Biological Standards and Control (NIBSC). Unsuccessful trials of treatment for iVDPV are displayed from 1999 to 2003. Persistent iVDPV carriage is then demonstrated to last positive sample, November 2018. Initial negative stool samples following remdesivir therapy are shown. Patient stool samples remain negative to August 2022.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 2

  1. 2021, Polio eradication strategy 2022–2026: Delivering on a promise
  2. 2013, The approved list of biological agents, Heal Saf Exec, 1

Cited by

See all 17

Metadata

Authors
Bermingham, W. H., Canning, B., Wilton, T., Kidd, M., Klapsa, D., Majumdar, M., Sooriyakumar, K., Martin, J., & Huissoon, A. P.
Affiliations
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • Nottingham University Hospitals NHS Trust (GB)
  • Medicines and Healthcare products Regulatory Agency (GB)
  • UK Health Security Agency (GB)
Corresponding author
Bermingham, William Hywel
Venue
Frontiers in Immunology
Published
2023-03-03
Volume
14
Pages
1135834-1135834
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4323045444
Cited by
15
References
12
Citations by year
2026: 3 · 2025: 8 · 2024: 2 · 2023: 2
FWCI
2.95
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
University Hospitals Birmingham NHS Foundation Trust
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
  • Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
Keywords
vaccine-derived poliovirus, remdesivir, common variable immunodeficiency, viral persistence, COVID-19 pandemic, antiviral therapy, RNA-dependent RNA polymerase inhibition, polio eradication, ribavirin
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adenosine Monophosphate, Alanine, Female, Humans, Immunologic Deficiency Syndromes, Male, Middle Aged, Poliomyelitis, Poliovirus Vaccine, Oral, Poliovirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection. https://app.cochat.ai/papers/10.3389/fimmu.2023.1135834
The paper
Bermingham, W. H., Canning, B., Wilton, T., Kidd, M., Klapsa, D., Majumdar, M., Sooriyakumar, K., Martin, J., & Huissoon, A. P. (2023). Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1135834

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.